Views: 1,369 | Downloads:
167
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Efficacy of Etoricoxib for Pain Relief during Endometrial Biopsy; A Double Blind Randomized Controlled Trial
Tanprasertkul C 
,
Pongrojpow D
,
Pongrojpow D Objective: To compare the efficacy of oral etoricoxib and placebo for pain relief during endometrial biopsy.
Material and Method: A double-blind, randomized controlled trial that included 80 women who underwent
endometrial biopsy was done at Thammasat University Hospital between 1 September 2005 and 30 June
2006. Forty women were randomly allocated to the etoricoxib group (120 mg, tablet) and 40 to the placebo
group. The main outcome was the patient’s assessment of intensity of pain measured by visual analog scale
(VAS) before speculum insertion, during endometrial biopsy, immediately after endometrial biopsy, and 30
minutes after endometrial biopsy. Satisfactory score was also evaluated.
Results: Demographic data including age, BMI, previous vaginal deliveries, previous pelvic surgery and
history of curettage were not significantly different between the etoricoxib group and the placebo group.
Mean pain score in the etoricoxib group was not significantly lower when compared with the placebo group
during endometrial biopsy (5.0 + 1.7 versus 5.25 + 2.2, p = 0.7) and immediately after endometrial biopsy (2.1
+ 2.2 versus 2.8 + 1.7, p = 0.1) but significantly lower at 30 minutes after endometrial biopsy (0.2 + 0.5 versus
0.6 + 0.8, p = 0.01). Mean satisfactory score was significantly higher in the etoricoxib group (6.9 + 1.8 versus
5.1 + 2.3, p = 0.001).
Conclusion: A single oral dose of etoricoxib for reduction of pain during endometrial biopsy had not significantly
lower the pain score during the procedure compared with the placebo. However mean satisfactory
score in the etoricoxib group was higher with statistically significant difference. Also the authors found no
serious adverse effects of this drug.
Keywords: Pain, Visual analog scale, Etoricoxib, Endometrial biopsy
Material and Method: A double-blind, randomized controlled trial that included 80 women who underwent
endometrial biopsy was done at Thammasat University Hospital between 1 September 2005 and 30 June
2006. Forty women were randomly allocated to the etoricoxib group (120 mg, tablet) and 40 to the placebo
group. The main outcome was the patient’s assessment of intensity of pain measured by visual analog scale
(VAS) before speculum insertion, during endometrial biopsy, immediately after endometrial biopsy, and 30
minutes after endometrial biopsy. Satisfactory score was also evaluated.
Results: Demographic data including age, BMI, previous vaginal deliveries, previous pelvic surgery and
history of curettage were not significantly different between the etoricoxib group and the placebo group.
Mean pain score in the etoricoxib group was not significantly lower when compared with the placebo group
during endometrial biopsy (5.0 + 1.7 versus 5.25 + 2.2, p = 0.7) and immediately after endometrial biopsy (2.1
+ 2.2 versus 2.8 + 1.7, p = 0.1) but significantly lower at 30 minutes after endometrial biopsy (0.2 + 0.5 versus
0.6 + 0.8, p = 0.01). Mean satisfactory score was significantly higher in the etoricoxib group (6.9 + 1.8 versus
5.1 + 2.3, p = 0.001).
Conclusion: A single oral dose of etoricoxib for reduction of pain during endometrial biopsy had not significantly
lower the pain score during the procedure compared with the placebo. However mean satisfactory
score in the etoricoxib group was higher with statistically significant difference. Also the authors found no
serious adverse effects of this drug.
Keywords: Pain, Visual analog scale, Etoricoxib, Endometrial biopsy
Download:
PDF